About 50 mg of stool per sample. That is the amount our lab requests for untargeted metabolomics, and it is exactly what Zhao and colleagues extracted in Frontiers in Endocrinology from 44 adults with cardiovascular-kidney-metabolic (CKM) syndrome, pairing 50 mg of feces in 4:1 methanol:water with 100 µL of fasting serum. Mass turned out to be the easy part. The harder question is whether the stool layer adds anything a blood draw would miss, and this paper gives an unusually

Statins have blunted what a standard lipid panel can tell a vascular surgeon. With low-density lipoprotein cholesterol (LDL-C) under control, patients with peripheral artery disease (PAD) look alike on paper, yet some still go on to a heart attack, stroke, or cardiovascular death after revascularization. Writing in BMC Cardiovascular Disorders, Cao and colleagues applied plasma multi-omics, pairing untargeted metabolomics with data-independent acquisition (DIA) proteomics, to

Most people with amnestic mild cognitive impairment (aMCI) are first seen in community clinics, where amyloid PET is rarely an option and plasma p-tau217 turns positive only once pathology has built up. Shan and colleagues tested whether deep plasma proteomics could see earlier. From 100 microliters of plasma per person in 84 adults, they identified 4,268 proteins by data-independent acquisition (DIA) mass spectrometry and distilled a 12-protein panel. It beat Simoa amyloid a

No blood test yet tells oncologists which patients with advanced breast cancer will progress early on trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC) that delivers a topoisomerase I payload to HER2-expressing cells. A September 2026 study in Frontiers in Oncology went after that gap with paired plasma multi-omics. The authors profiled the proteome and metabolome of 16 patients before treatment and after two cycles, then screened baseline features against prog

After curative resection of hepatocellular carcinoma (HCC), surveillance relies on serum AFP, DCP, and periodic MRI, all of which tend to catch relapse late. Could urine do better? Xing and colleagues tracked 378 patients with urinary proteomics, pairing data-independent acquisition (DIA) discovery with parallel reaction monitoring (PRM) verification, and built a score that flagged recurrence a median of 4.1 months before imaging. Key Takeaways Urinary proteomics can track li